Abstract: A wearable drug delivery device includes an injector having a housing, a reservoir, a needle or cannula, a drive mechanism for urging drug product out of the reservoir, through the needle or cannula, and to a patient, and an activator mechanism disposed on a surface of the housing for activating the drive mechanism. An activation prevention mechanism is coupled to the injector housing and/or activation prevention mechanism to prevent inadvertent actuation of the activator mechanism.

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

Abstract: Delivery devices for administering drugs are disclosed. An example apparatus, includes a body including: a handle in which a syringe assembly is to be disposed; a base having a bottom face to be disposed adjacent a user; and an absorbent material attached to the bottom face, the absorbent material structured to hold a fluid to be released onto the user prior to or during an injection procedure.

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.

Abstract: Drug delivery devices are described that provide hybrid forms with optional gripping functionalities. For example, the devices can include a grip portion on a skin contact surface with a release liner disposed thereon. A user can operate the devices with the release liner disposed on the grip portion or can remove the release liner so that the grip portion is able to aid users in orienting and supporting the device during an injection operation.

Abstract: Drug delivery devices are described that provide hybrid forms with gripping and stability functionalities, such as a grip portion on a skin contact surface. In some versions, the drug delivery devices can include a cap having a release liner such that removal of the cap exposes the grip portion. In some versions, the drug delivery devices include a retractable needle guard having the grip portion extending therearound.

Abstract: An example drug delivery device includes a syringe assembly including a needle. The drug delivery device includes a handle carrying the syringe assembly and including a first portion, a second portion, a tapered surface, and a window. The first portion being wider than the second portion. The tapered surface extending from the first portion to the second portion. The needle of the syringe assembly adapted to extend from adjacent the second portion during an injection procedure. The window positioned between the first portion and the second portion and adapted to allow contents of the drug delivery device to be viewed. The drug delivery device includes a base adapted to be positioned adjacent the second portion of the handle during at least the injection procedure. The base being wider than the second portion of the handle and adapted to increase stability of the drug delivery device during the injection procedure.

Abstract: Drug delivery devices and related arrangements are disclosed. A drug delivery device may include a housing having an opening, a drug storage container including a delivery member with an insertion end configured to extend at least partially through the opening, and a plunger. A drive mechanism may be included for driving the plunger in a distal direction to expel a drug from the drug storage container through the delivery member upon activation. The drug delivery device may additionally include a guard moveably disposed adjacent to the opening and operably coupled to the drive mechanism for activation of the drive mechanism. A lock may be selectively engageable with the guard to limit movement of the guard in the proximal direction. An indicator may be coupled to the drive mechanism to generate an audible signal during drug delivery, and to cease generating the audible signal when drug delivery is complete.

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.

Abstract: Various novel arrangements for facilitating adherence of an on-body injector onto a patient's skin and subsequently removing the injector after drug delivery has occurred. Such arrangements can include adhesive configurations that conform to body contours, adhesive configurations that include pull rings or chords, tabs, or perforated seams to facilitate one-step or two-step removal, and/or injector bodies with gripping features to facilitate manual grasping.